Please Wait
Applying Filters...
menu
    • menu
    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2026 highlights: Astra, CSPC sign up to US$ 18.5 bn obesity deal; Wegovy’s pill version debuts in US

    Stock Recap
    #PipelineProspector

    Menu

    Valrubicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    29/01/2026 TAPI Technology & API Services
    Israel
    		 TAPI NL BV 12405 VALRUBICIN (AD-32) 1997-03-05 Active II N/A
    29/01/2026 DZD Heze Pharmaceutical Co Ltd
    China
    		 DZD (HEZE) PHARMACEUTICAL CO LTD 34521 VALRUBICIN 2020-04-30 Active II N/A
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.